{"entity": "publication", "iuid": "191a7cb2999546c3abc8f4a4fa498849", "timestamp": "2026-09-23T17:44:32.542Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/191a7cb2999546c3abc8f4a4fa498849.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/191a7cb2999546c3abc8f4a4fa498849"}}, "title": "Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.", "authors": [{"family": "Havervall", "given": "Sebastian", "initials": "S"}, {"family": "Marking", "given": "Ulrika", "initials": "U"}, {"family": "Greilert-Norin", "given": "Nina", "initials": "N"}, {"family": "Ng", "given": "Henry", "initials": "H"}, {"family": "Gordon", "given": "Max", "initials": "M"}, {"family": "Salomonsson", "given": "Ann-Christin", "initials": "AC"}, {"family": "Hellstr\u00f6m", "given": "Cecilia", "initials": "C"}, {"family": "Pin", "given": "Elisa", "initials": "E"}, {"family": "Blom", "given": "Kim", "initials": "K"}, {"family": "Mangsbo", "given": "Sara", "initials": "S"}, {"family": "Phillipson", "given": "Mia", "initials": "M"}, {"family": "Klingstr\u00f6m", "given": "Jonas", "initials": "J"}, {"family": "Hober", "given": "Sophia", "initials": "S"}, {"family": "Nilsson", "given": "Peter", "initials": "P"}, {"family": "\u00c5berg", "given": "Mikael", "initials": "M"}, {"family": "Th\u00e5lin", "given": "Charlotte", "initials": "C"}], "type": "journal article", "published": "2021-08-00", "journal": {"title": "EBioMedicine", "issn": "2352-3964", "volume": "70", "pages": "103523", "issn-l": "2352-3964"}, "abstract": "Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. Data on immune responses following a single-dose adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein (ChAdOx1 nCoV-19) in individuals with previous SARS-CoV-2 infection are however limited, and current guidelines recommend a two-dose regimen regardless of preexisting immunity.\n\nWe compared RBD-specific IgG and RBD-ACE2 blocking antibodies against SARS-CoV-2 wild type and variants of concern following two doses of the mRNA vaccine BNT162b2 in SARS-CoV-2 na\u00efve healthcare workers (n=65) and a single dose of the adenovector vaccine ChAdOx1 nCoV-19 in 82 healthcare workers more than (n=45) and less than (n=37) 11 months post mild SARS-CoV-2 infection at time of vaccination.\n\nThe post-vaccine levels of RBD-specific IgG and neutralizing antibodies against the SARS-CoV-2 wild type and variants of concern including Delta lineage 1.617.2 were similar or higher in participants receiving a single dose of ChAdOx1 nCoV-19 vaccine post SARS-CoV-2 infection (both more than and less than 11 months post infection) compared to SARS-CoV-2 na\u00efve participants who received two doses of BNT162b2 vaccine.\n\nOur data support that a single dose ChAdOx1 nCoV-19 vaccine that is administered up to at least 11 months post SARS-CoV-2 infection serves as an effective immune booster. This provides a possible rationale for a single-dose vaccine regimen.\n\nA full list of funding bodies that contributed to this study can be found in the Acknowledgements section.", "doi": "10.1016/j.ebiom.2021.103523", "pmid": "34391088", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8357428"}, {"db": "pii", "key": "S2352-3964(21)00316-9"}], "notes": [], "created": "2026-09-23T08:47:42.854Z", "modified": "2026-09-23T08:47:42.876Z"}